Literature DB >> 11966745

Reduced capillary permeability and capillary density in the skin of GH-deficient adults: improvement after 12 months GH replacement.

P H N Oomen1, J A M Beentjes, E Bosma, A J Smit, W D Reitsma, R P F Dullaart.   

Abstract

OBJECTIVE: Several lines of evidence suggest that the GH-IGF-1 axis affects capillary permeability and angiogenesis. We evaluated skin capillary permeability and capillary density in GH-deficient adults, before and after GH replacement therapy. PATIENTS: Seven normotensive, nondiabetic GH-deficient adults (two women) were matched with 14 control subjects. MEASUREMENTS: Large-window videodensitometry with sodium fluorescein was performed in all subjects. Capillary permeability was expressed as the average relative light intensity over the first 7 min after the appearance of fluorescein in the skin capillaries; Iav(7). Skin capillary density was determined by counting the visualized capillaries and was expressed as n/mm2. The GH-deficient patients were restudied after 12 months of GH replacement therapy (2 U/day).
RESULTS: Both capillary permeability and capillary density were lower in untreated GH-deficient patients than in control subjects (median, interquartile range): Iav(7) in GH-deficient patients 47.1 (45.1-52.2)% vs. 57.5 (50.5-64.8)% in controls, P < 0.05; capillary density in GH-deficient patients 18 (12-24)/mm2 vs. 32 (26-36)/mm2 in controls, P < 0.05. GH treatment normalized plasma IGF-1 from 4.3 (1.0-13.4) to 22.2 (19.8-48.2) nmol/l (P < 0.05). Furthermore, both capillary permeability [Iav(7) 53.1 (48.8-58.4)%, P < 0.05] and capillary density [26 (17-34)/mm2, P < 0.05] increased to a level that was not different from that in control subjects.
CONCLUSIONS: The present study demonstrates that the growth hormone deficiency syndrome is associated with microvascular alterations, which are responsive to growth hormone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11966745     DOI: 10.1046/j.1365-2265.2002.01517.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  The contribution of growth hormone to mammary neoplasia.

Authors:  Jo K Perry; Kumarasamypet M Mohankumar; B Starling Emerald; Hichem C Mertani; Peter E Lobie
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-07       Impact factor: 2.673

Review 2.  Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.

Authors:  Diego Caicedo; Pablo Devesa; Víctor M Arce; Julia Requena; Jesús Devesa
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-12-22

Review 3.  Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?

Authors:  Jesús Devesa; Cristina Almengló; Pablo Devesa
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2016-10-12

4.  Titrating Growth Hormone Dose to High-Normal IGF-1 Levels Has Beneficial Effects on Body Fat Distribution and Microcirculatory Function Despite Causing Insulin Resistance.

Authors:  Christa C van Bunderen; Rick I Meijer; Paul Lips; Mark H Kramer; Erik H Serné; Madeleine L Drent
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-09       Impact factor: 5.555

Review 5.  Growth Hormone (GH) and Cardiovascular System.

Authors:  Diego Caicedo; Oscar Díaz; Pablo Devesa; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.